Bendell, J. C., Uronis, H. E., Morse, M. A., Blobe, G., Aklilu, M., Nixon, A., … Hurwitz, H. (2008). Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC). Journal of Clinical Oncology, 26(15_suppl), 4063–4063. https://doi.org/10.1200/jco.2008.26.15_suppl.4063

Bendell, J. C., H. E. Uronis, M. A. Morse, G. Blobe, M. Aklilu, A. Nixon, D. Niedzweicki, W. Honeycutt, L. Howard, and H. Hurwitz. “Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC).” Journal of Clinical Oncology 26, no. 15_suppl (May 20, 2008): 4063–4063. https://doi.org/10.1200/jco.2008.26.15_suppl.4063.

Bendell JC, Uronis HE, Morse MA, Blobe G, Aklilu M, Nixon A, et al. Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 2008 May 20;26(15_suppl):4063–4063.

Bendell, J. C., et al. “Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC).” Journal of Clinical Oncology, vol. 26, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2008, pp. 4063–4063. Crossref, doi:10.1200/jco.2008.26.15_suppl.4063.

Bendell JC, Uronis HE, Morse MA, Blobe G, Aklilu M, Nixon A, Niedzweicki D, Honeycutt W, Howard L, Hurwitz H. Initial results of a phase II study of oxaliplatin (OX), capecitabine (CAP), bevacizumab (BV), and cetuximab (CET) in the treatment of metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2008 May 20;26(15_suppl):4063–4063.